Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox®, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix’s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer. Generating insights from tumor-host interaction in order to detect cancer as early as possible and tailor the right treatment for the right patient. We are pioneering the field of immuno-transcriptomics with passion for improving health outcomes.
B2B
1 to 25
Funded
€1 M
Scaling Up
2014
Pharmaceuticals and Medical Products
Healthcare
Health Care Facilities & Hospitals
Biotechnology
N/A
Cancer Treatment Research
Production
IT and Security
Service
Yes
Active
Machine Learning
Machine Perception
Natural Language Processing
Knowledge Representation and Reasoning
N/A
Software & Hardware
N/A
N/A
Potential Customers
Interested in what they do or partnership?
Learn more about how they work
